Upsher-Smith launches Tosymra

Sandra Levy
Senior Editor
Sandra Levy profile picture

Upsher-Smith is introducing Tosymra (sumatriptan) nasal spray, in a dosage strength of 10 mg for the acute treatment of migraine with or without aura in adults. Tosymra is a fast-acting, easy-to-use acute migraine treatment option that delivers the efficacy of an injectable in a convenient nasal spray.

Tosymra, which was approved by the  Food and Drug Administration in early 2019, was recently acquired by Upsher-Smith from Dr. Reddy’s in a strategic effort to expand and diversify the company’s migraine portfolio.

Tosymra is supported by Upsher-Smith’s Access Pathways Program, which provides savings and support services for patients. The Platinum Pass savings card enables commercially insured patients to pay as little as $0 per prescription.

“We’re excited to launch Tosymra, the third product in Upsher-Smith’s growing migraine portfolio, which includes Qudexy XR and Zembrace SymTouch,” Upsher-Smith president and CEO Rusty Field said. “Many patients face challenges during migraine attacks that make available acute treatment options inadequate. Tosymra Nasal Spray offers an alternative for patients whose symptoms interfere with taking oral medication or who may be dissatisfied with their current treatment regimen.”